GlycoMimetics Stock (NASDAQ:GLYC), Trade Ideas

GlycoMimetics

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ATXG

CLDI

CLEU

CREV

FWBI

GLYC

MDIA

NEXI

PNST

RVSN

SASI

TPHS

VNRX

VRAX

YOSH

ZCAR

Shares of  Trinity Place Holdings Inc. (NYSE: TPHS) rose sharply in pre-market trading.

The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan. 31, 2024.

Trinity Place shares jumped 80.1% to $0.2056 in pre-market trading.

Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket

Intraday Update

AGBA

AMBI

ANGN

ARCT

ASTS

ATAI

BANL

BCLI

BLUE

BRDS

CALM

CDAK

CIFR

DPRO

ENVX

ERAS

GIFI

HLBZ

ICCM

LGMK

LOCL

LOCO

LULU

MARA

MINM

NABL

PIRS

PRQR

RIOT

RIVN

SHCR

SLGC

SSYS

STEM

Tempest Therapeutics, Inc. - Common Stock

TPST

WAVD

Gainers


	LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million.


Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

ACAD

CING

CYTO

CZOO

HYPR

LASE

MEDS

Meten EdtechX Education Group Ltd Ordinary Shares

METX

MSTR

MTEM

OBSV

PRVB

SYTA

TENX

Gainers


	Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.


Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket

GlycoMimetics Inc

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares rose 43.48% to $0.49. The market value of their outstanding shares is at $23.1 million. </li>
<li>Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) shares rose 20.77% to $6.57. The market value of their outstanding shares is at $325.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 16.59% to $0.05. The market value of their outstanding shares is at $1.7 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 6.41% to $3.15. The market value of their outstanding shares is at $203.0 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 6.01% to $1.05. The market value of their outstanding shares is at $11.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock decreased by 14.1% to $0.98 during Tuesday's after-market session. The market value of their outstanding shares is at $7.1 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock fell 12.0% to $2.2. The market value of their outstanding shares is at $2.7 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares declined by 7.43% to $1.62. The market value of their outstanding shares is at $15.2 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares decreased by 6.55% to $1.0. The market value of their outstanding shares is at $14.7 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 6.17% to $1.37. The market value of their outstanding shares is at $39.3 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares decreased by 4.9% to $1.36. The market value of their outstanding shares is at $27.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

BNOX

CUTR

CYTH

ENVB

IMNN

MIRA

ONMD

SGHT

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock moved upwards by 5.26% to $0.6. The company's market cap stands at $14.2 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares rose 5.12% to $1.23. The company's market cap stands at $33.4 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 5.07% to $2.69. The market value of their outstanding shares is at $103.0 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock rose 4.79% to $1.75. The company's market cap stands at $130.7 million. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock increased by 4.7% to $6.9. The market value of their outstanding shares is at $16.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) stock fell 12.5% to $0.39 during Wednesday's after-market session. The market value of their outstanding shares is at $13.6 million. As per the press release, Q4 earnings came out today. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock declined by 9.36% to $0.34. The company's market cap stands at $4.0 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) stock declined by 9.24% to $1.77. The company's market cap stands at $54.8 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock fell 8.81% to $2.9. The company's market cap stands at $186.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares fell 5.15% to $7.0. The market value of their outstanding shares is at $5.2 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) stock declined by 5.01% to $0.99. The company's market cap stands at $6.5 million. The company's, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALZN

ATHA

AVTX

BIOR

CLSD

FRES

MODD

SSKN

TFFP

TTNP

YTEN

12 Health Care Stocks Moving In Wednesday's After-Market Session

HC Wainwright &amp; Co. analyst Edward White maintains GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) with a Buy and maintains $8 price target.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on GlycoMimetics, Maintains $8 Price Target

GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 26.32 percent increase over losses of $(0.19) per share from the same period last year.&nbsp;

Earnings

GlycoMimetics Q4 EPS $(0.14) Beats $(0.15) Estimate, Cash Balance of $41.8M

<h3>Companies Reporting Before The Bell</h3>
&bull; Local Bounti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOCL#NYSE">LOCL</a>) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
&bull; REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) is estimated to report quarterly loss at $2.38 per share on revenue of $1.35 million.
&bull; Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is projected to report quarterly loss at $2.05 per share on revenue of $12.48 million.
&bull; Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is expected to report quarterly loss at $0.05 per share on revenue of $19.66 million.
&bull; Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is expected to report earnings for its fourth quarter.
&bull; Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is likely to report earnings for its fourth quarter.
&bull; Gamida Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMDA#NASDAQ">GMDA</a>) is projected to report quarterly loss at $0.15 per share on revenue of $1.06 million.
&bull; PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is likely to report earnings for its fourth quarter.
&bull; Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) is projected to report earnings for its fourth quarter.
&bull; Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) is estimated to report quarterly loss at $1.14 per share on revenue of $2.00 million.
&bull; Lands&#39; End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $502.71 million.
&bull; Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is projected to report quarterly earnings at $3.58 per share on revenue of $2.39 billion.
&bull; GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) is projected to report earnings for its fourth quarter.
&bull; Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter.
&bull; UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) is projected to report quarterly earnings at $1.42 per share on revenue of $587.84 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report quarterly loss at $0.48 per share on revenue of $30.20 million.
&bull; Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is likely to report earnings for its fourth quarter.
&bull; VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly loss at $0.18 per share on revenue of $279.03 million.
&bull; RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $777.48 million.
&bull; American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.19 million.
&bull; Cosan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $7.45 billion.
&bull; Greenidge Generation Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $26.70 million.
&bull; Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $21.00 million.
&bull; Allied Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGAE#NASDAQ">AGAE</a>) is projected to report earnings for its fourth quarter.
&bull; Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $1.52 billion.
&bull; LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) is expected to report quarterly loss at $1.73 per share on revenue of $2.28 million.
&bull; H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.64 per share on revenue of $825.03 million.
&bull; Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $188.73 million.
&bull; Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $38.21 million.
&bull; Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.33 per share on revenue of $2.48 million.
&bull; Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) is expected to report earnings for its fourth quarter.
&bull; BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $90 thousand.
&bull; Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $45.25 million.
&bull; Silver Spike Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSIC#NASDAQ">SSIC</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $3.37 million.
&bull; Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $28.94 million.
&bull; PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $32.27 million.
&bull; Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $20.43 million.
&bull; Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $62.02 million.
&bull; Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) is estimated to report quarterly loss at $1.20 per share on revenue of $9.30 million.
&bull; Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $4.60 million.
&bull; Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.01 million.
&bull; Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $0.97 per share on revenue of $263.12 million.
&bull; Eastside Distilling (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) is projected to report quarterly loss at $0.90 per share on revenue of $3.68 million.
&bull; Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is likely to report quarterly loss at $0.05 per share on revenue of $124.86 million.
&bull; Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) is expected to report quarterly loss at $0.11 per share on revenue of $82.04 million.
&bull; Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) is expected to report quarterly loss at $0.05 per share on revenue of $50 thousand.
&bull; Kingstone Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KINS#NASDAQ">KINS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $29.65 million.
&bull; MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $909.50 million.
&bull; Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) is likely to report quarterly loss at $0.22 per share on revenue of $28.13 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AGAE

AQMS

BCDA

BRZE

CELC

CLRB

CMCT

CSAN

CTAS

CWCO

DLNG

DRRX

DTIL

EAST

EDAP

GAIA

GMDA

GREE

KINS

MDAI

MLKN

PDSB

PLBY

SNDA

SSIC

SYRS

UGRO

USIO

VNET

VRNT

Earnings Scheduled For March 27, 2024

GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Here's what investors need to know before the announcement.
Analysts estimate that GlycoMimetics will report an earnings per share (EPS) of $-0.15. 
GlycoMimetics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 0.0% drop in the share price the next day.
Here's a look at GlycoMimetics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.18</td>
<td>-0.17</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.14</td>
<td>-0.13</td>
<td>-0.17</td>
<td>-0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>2.0%</td>
<td>7.000000000000001%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711468846_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of GlycoMimetics were trading at $2.82 as of March 25. Over the last 52-week period, shares are up 120.47%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GLYC/earnings">To track all earnings releases for GlycoMimetics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For GlycoMimetics

<h3>Gainers</h3>
<ul>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) shares rose 49.2% to $0.34 during Wednesday's after-market session. The market value of their outstanding shares is at $9.9 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock rose 25.88% to $0.44. The company's market cap stands at $11.6 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares rose 25.0% to $0.3. The company's market cap stands at $7.7 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares rose 22.9% to $0.18. The company's market cap stands at $4.0 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares moved upwards by 12.84% to $0.27. The market value of their outstanding shares is at $48.8 million. </li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock increased by 8.74% to $10.82. The market value of their outstanding shares is at $32.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock declined by 14.2% to $0.27 during Wednesday's after-market session. The company's market cap stands at $1.1 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares declined by 7.47% to $2.85. The market value of their outstanding shares is at $183.5 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) stock fell 6.44% to $4.07. The company's market cap stands at $5.9 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares declined by 5.89% to $0.44. The market value of their outstanding shares is at $1.1 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 5.41% to $1.4. The company's market cap stands at $4.3 million. </li>
<li>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) stock declined by 5.16% to $34.05. The market value of their outstanding shares is at $692.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFIB

BGXX

EFTR

KZIA

ONCO

SBFM

SILO

SINT

THAR

TRML

Health Care

General

Glycomimetics Announced Initial Safety, Tolerability, And Pharmacokinetic Results From Phase 1A Study Of GMI-1687 In Healthy Volunteers, Meeting Its Primary And Secondary Endpoints With No Dose-Limiting Toxicities Or Safety Signals

Shares of Trinity Place Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tphs#NYSE">TPHS</a>) rose sharply in pre-market trading.
The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan. 31, 2024.
Trinity Place shares jumped 80.1% to $0.2056 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Sigma Additive Solutions, Inc.(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sasi#NASDAQ">SASI</a>) gained 68.6% to $4.89 in pre-market trading. Sigma Additive Solutions was recently granted U.S. patent #11858207: Defect detection for additive manufacturing systems.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crev#NASDAQ">CREV</a>) rose 36.8% to $31.88 in pre-market trading.</li>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) shares rose 29.5% to $1.62 in pre-market trading after dipping over 15% on Tuesday.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) shares gained 25.9% to $4.81 in pre-market trading. Roth MKM raised price target on the stock to $40.</li>
<li>China Liberal Education Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cleu#NASDAQ">CLEU</a>) gained 17.2% to $0.2218 in pre-market trading.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) shares rose 13.9% to $2.79 in pre-market trading after gaining over 6% on Tuesday.</li>
<li>VolitionRx Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vnrx#NYSE">VNRX</a>) shares climbed 11.4% to $1.17 in pre-market trading after jumping over 46% on Tuesday.</li>
<li>Ucommune International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uk#NASDAQ">UK</a>) shares gained 10.6% to $4.48 in pre-market trading after gaining 9% on Tuesday.</li>
<li>GlycoMimetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glyc#NASDAQ">GLYC</a>) gained 10.3% to $3.00 in pre-market trading. GlycoMimetics entered into project agreement with Patheon Manufacturing Services, part of Thermo Fisher Scientific.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Addentax Group Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxg#NASDAQ">ATXG</a>) shares fell 16.8% to $1.23 in pre-market trading.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) shares fell 13.8% to $1.24 in pre-market trading after declining around 5% on Tuesday.</li>
<li>Virax Biolabs Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrax#NASDAQ">VRAX</a>) shares fell 13.1% to $1.19 in pre-market trading after declining 8% on Tuesday.</li>
<li>Pinstripes (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pnst#NYSE">PNST</a>) shares fell 13% to $11.58 in pre-market trading after surging 22% on Tuesday. Pinstripes and Banyan Acquisition Corporation announced they have closed their previously announced business combination, which was approved by Banyan&rsquo;s stockholders at a meeting on Dec. 27, 2023.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) shares fell 12.4% to $5.96 in pre-market trading after gaining 25% on Tuesday.</li>
<li>MediaCo Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdia#NASDAQ">MDIA</a>) shares fell 11.1% to $0.5230 in pre-market trading after jumping around 37% on Tuesday.</li>
<li>Aclarion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acon#NASDAQ">ACON</a>) shares fell 10% to $0.1853 in pre-market trading. Aclarion announced a 1-for-16 reverse stock split.</li>
<li>Signing Day Sports, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sgn#NYSE">SGN</a>) fell 9.7% to $0.9508 in pre-market trading after declining around 7% on Tuesday.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcar#NASDAQ">ZCAR</a>) shares fell 8.4% to $2.74 in pre-market trading after dipping around 19% on Tuesday.</li>
<li>Polished.com Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pol#NYSE">POL</a>) fell 8.1% to $8.44 in pre-market trading after jumping 52% on Tuesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36463824/cal-maine-foods-unifirst-and-3-stocks-to-watch-heading-into-wednesday"> Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesday</a>
&nbsp;

Biotech

GlycoMimetics Entered Into Project Agreement With Patheon Manufacturing Services, Part Of Thermo Fisher Scientific; Patheon Will Manufacture, Supply Co With Drug Candidate, Uproleselan, For Commercial Sale Should Co Receive Marketing Approval From FDA

Capital One analyst Zegbeh Jallah initiates coverage on GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) with a Overweight rating and announces Price Target of $12.

Initiation

Capital One Initiates Coverage On GlycoMimetics with Overweight Rating, Announces Price Target of $12

<h3>Companies Reporting Before The Bell</h3>
&bull; Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
&bull; Dominion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $4.38 billion.
&bull; Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) is estimated to report quarterly earnings at $0.45 per share on revenue of $390.96 million.
&bull; Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $150.66 million.
&bull; Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $8.25 billion.
&bull; Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) is likely to report earnings for its third quarter.
&bull; Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $987.00 million.
&bull; TELUS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $5.08 billion.
&bull; TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $657.82 million.
&bull; Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $1.09 billion.
&bull; Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $1.88 billion.
&bull; Cinemark Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $834.58 million.
&bull; Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $702.46 million.
&bull; Icahn Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEP#NASDAQ">IEP</a>) is likely to report quarterly earnings at $0.34 per share on revenue of $2.71 billion.
&bull; Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) is expected to report quarterly loss at $0.57 per share on revenue of $3.42 million.
&bull; Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $2.58 billion.
&bull; iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $16.17 million.
&bull; Moog Inc. Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOG#NYSE">MOG</a>) is projected to report quarterly earnings at $1.71 per share on revenue of $806.33 million.
&bull; Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZY#NASDAQ">LAZY</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $307.87 million.
&bull; Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) is expected to report earnings for its third quarter.
&bull; US Silica Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLCA#NYSE">SLCA</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $380.20 million.
&bull; Brookfield Bus Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBU#NYSE">BBU</a>) is expected to report earnings for its third quarter.
&bull; Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) is projected to report quarterly earnings at $1.96 per share on revenue of $1.39 billion.
&bull; Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $12.56 billion.
&bull; Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $14.43 billion.
&bull; Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) is projected to report quarterly earnings at $1.00 per share on revenue of $3.68 billion.
&bull; American Axle &amp; Mfg Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $1.50 billion.
&bull; Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) is projected to report quarterly earnings at $1.86 per share on revenue of $479.89 million.
&bull; Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $3.89 billion.
&bull; Magna International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) is estimated to report quarterly earnings at $1.34 per share on revenue of $10.33 billion.
&bull; E W Scripps (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) is likely to report quarterly loss at $0.22 per share on revenue of $565.97 million.
&bull; Koppers Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) is likely to report quarterly earnings at $1.26 per share on revenue of $559.00 million.
&bull; Telephone and Data (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) is likely to report quarterly loss at $0.11 per share on revenue of $1.28 billion.
&bull; United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $1.00 billion.
&bull; W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) is likely to report quarterly earnings at $0.63 per share on revenue of $450.17 million.
&bull; GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) is expected to report earnings for its third quarter.
&bull; Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is estimated to report quarterly loss at $0.31 per share on revenue of $5.55 million.
&bull; Shenandoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHEN#NASDAQ">SHEN</a>) is likely to report quarterly loss at $0.01 per share on revenue of $71.18 million.
&bull; AMC Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $657.80 million.
&bull; inTest (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INTT#AMEX">INTT</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $32.65 million.
&bull; Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) is projected to report quarterly earnings at $0.30 per share on revenue of $122.61 million.
&bull; FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) is expected to report quarterly loss at $0.32 per share on revenue of $286.18 million.
&bull; Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $877.78 million.
&bull; Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) is likely to report quarterly earnings at $1.41 per share on revenue of $54.76 billion.
&bull; AdvanSix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIX#NYSE">ASIX</a>) is projected to report quarterly loss at $0.03 per share on revenue of $367.90 million.
&bull; Ares Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRE#NYSE">ACRE</a>) is estimated to report quarterly earnings at $0.21 per share on revenue of $25.32 million.
&bull; Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) is expected to report quarterly earnings at $1.04 per share on revenue of $5.07 billion.
&bull; Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) is expected to report quarterly loss at $0.33 per share on revenue of $63.41 million.
&bull; Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRP#NYSE">NRP</a>) is projected to report earnings for its third quarter.
&bull; Marcus &amp; Millichap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMI#NYSE">MMI</a>) is expected to report quarterly loss at $0.26 per share on revenue of $164.80 million.
&bull; Northwest Natural Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>) is likely to report quarterly loss at $0.67 per share on revenue of $134.78 million.
&bull; Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEPC#NYSE">BEPC</a>) is expected to report earnings for its third quarter.
&bull; Interface (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $324.75 million.
&bull; Atlanta Braves Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRK#NASDAQ">BATRK</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $268.70 million.
&bull; Atlanta Braves Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATRA#NASDAQ">BATRA</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $268.50 million.
&bull; Qurate Retail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEB#NASDAQ">QRTEB</a>) is estimated to report earnings for its third quarter.
&bull; Qurate Retail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEA#NASDAQ">QRTEA</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $2.54 billion.
&bull; Liberty Formula One Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $900.58 million.
&bull; Liberty Formula One Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONA#NASDAQ">FWONA</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $895.00 million.
&bull; Liberty SiriusXM Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSXMK#NASDAQ">LSXMK</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $2.30 billion.
&bull; Liberty SiriusXM Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSXMA#NASDAQ">LSXMA</a>) is expected to report quarterly earnings at $0.85 per share on revenue of $2.30 billion.
&bull; Liberty Broadband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDK#NASDAQ">LBRDK</a>) is estimated to report quarterly earnings at $2.43 per share on revenue of $257.00 million.
&bull; Liberty Broadband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) is expected to report quarterly earnings at $2.18 per share on revenue of $252.20 million.
&bull; GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) is projected to report quarterly loss at $0.03 per share on revenue of $180.00 million.
&bull; Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) is projected to report quarterly earnings at $0.68 per share on revenue of $1.43 billion.
&bull; MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is projected to report quarterly earnings at $1.80 per share on revenue of $14.31 billion.
&bull; Brookfield Business (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBUC#NYSE">BBUC</a>) is estimated to report earnings for its third quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) is projected to report quarterly earnings at $0.99 per share on revenue of $3.29 billion.
&bull; Trinseo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSE#NYSE">TSE</a>) is likely to report quarterly loss at $0.96 per share on revenue of $973.00 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

GlycoMimetics Stock (NASDAQ:GLYC), Trade Ideas